Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Cepheid Xpert Xpress SARS-CoV-2 Test

ASPR’s Portfolio of COVID-19 Medical Countermeasures under  EUA

BARDA is supporting the development of Cepheid’s Xpert Xpress SARS-CoV-2 test , which is a rapid, real-time RT-PCR test that detects viral RNAus in nasopharyngal nasopharyngeal, oropharyngeal, nasal, or mid-turbinate swabs and/or nasal wash/aspirate  swab and nasal wash/aspirate samples. within 45 minutes. The test provides results in approximately 30 minutes in high titer samples and results for negative samples in 45 minutes.  The test works on all GeneXpert Dx and Infinity systems in the laboratory, as well as the GeneXpert Express system at the point of care. To learn more, see the award announcement.

Emergency Use Authorization

On March 20, 2020, FDA issued an Emergency Use Authorization (EUA) to allow Cepheid’s Xpert Xpress SARS-CoV-2 test to be used to diagnose COVID-19.

  • This page last reviewed: May 21, 2020